Abstract
Parkinson’s disease (PD) is associated with higher risk of cognitive impairment that may lead to memory loss, confusion, and decreased attention span. In this study, we have investigated the effect of GW0742, a PPAR-β/δ agonist in rat model of cognitive impairment associated with PD. Bilateral intranigral administration of 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP) (100 µg/1 µl/side) produced significant cognitive dysfunctions. PPAR-β/δ agonist GW0742 at a dose of 30 and 100 µg/kg showed significant improvement in cognitive impairments caused by MPTP in rat model of PD as evident from passive avoidance and Morris water maze test. MPTP-induced massive oxidative damage and DNA fragmentation was ameliorated by GW0742 treatment as observed after MDA and GSH estimation and TUNEL assay. Tyrosine hydroxylase positive neurons were decreased by 25% of normal control in MPTP group and GW0742 treatment restored tyrosine hydroxylase levels showing neuroprotective nature. Further, we performed physiologically based pharmacokinetic (PBPK) modeling study using GastroPlus to characterize the kinetics of GW0742 in the brain. The predicted amounts of GW0742 in brain suggest that it has the ability to cross the blood brain barrier. This study implicates the involvement of PPAR-β/δ in PD induced cognitive impairment.
Keywords: GastroPlus, GW0742, MPTP, parkinson’s disease, PBPK modeling, PPAR beta.
Current Neurovascular Research
Title:A PPAR-β/δ Agonist is Neuroprotective and Decreases Cognitive Impairment in a Rodent Model of Parkinson’s Disease
Volume: 11 Issue: 2
Author(s): Nihar R. Das, Rahul P. Gangwal, Mangesh V. Damre, Abhay T. Sangamwar and Shyam S. Sharma
Affiliation:
Keywords: GastroPlus, GW0742, MPTP, parkinson’s disease, PBPK modeling, PPAR beta.
Abstract: Parkinson’s disease (PD) is associated with higher risk of cognitive impairment that may lead to memory loss, confusion, and decreased attention span. In this study, we have investigated the effect of GW0742, a PPAR-β/δ agonist in rat model of cognitive impairment associated with PD. Bilateral intranigral administration of 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP) (100 µg/1 µl/side) produced significant cognitive dysfunctions. PPAR-β/δ agonist GW0742 at a dose of 30 and 100 µg/kg showed significant improvement in cognitive impairments caused by MPTP in rat model of PD as evident from passive avoidance and Morris water maze test. MPTP-induced massive oxidative damage and DNA fragmentation was ameliorated by GW0742 treatment as observed after MDA and GSH estimation and TUNEL assay. Tyrosine hydroxylase positive neurons were decreased by 25% of normal control in MPTP group and GW0742 treatment restored tyrosine hydroxylase levels showing neuroprotective nature. Further, we performed physiologically based pharmacokinetic (PBPK) modeling study using GastroPlus to characterize the kinetics of GW0742 in the brain. The predicted amounts of GW0742 in brain suggest that it has the ability to cross the blood brain barrier. This study implicates the involvement of PPAR-β/δ in PD induced cognitive impairment.
Export Options
About this article
Cite this article as:
Das R. Nihar, Gangwal P. Rahul, Damre V. Mangesh, Sangamwar T. Abhay and Sharma S. Shyam, A PPAR-β/δ Agonist is Neuroprotective and Decreases Cognitive Impairment in a Rodent Model of Parkinson’s Disease, Current Neurovascular Research 2014; 11 (2) . https://dx.doi.org/10.2174/1567202611666140318114037
DOI https://dx.doi.org/10.2174/1567202611666140318114037 |
Print ISSN 1567-2026 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5739 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Patents Review in siRNA Delivery for Pulmonary Disorders
Recent Patents on Drug Delivery & Formulation Selective Serotonin-norepinephrine Re-uptake Inhibition Limits Renovas-cular-hypertension Induced Cognitive Impairment, Endothelial Dysfunction, and Oxidative Stress Injury
Current Neurovascular Research Nanocapsulated Ascorbic Acid in Combating Cerebral Ischemia Reperfusion- Induced Oxidative Injury in Rat Brain
Current Alzheimer Research Application of Ozone Therapy in the Vestibulocochlear Syndrome
Reviews on Recent Clinical Trials Mitochondriotropic Cationic Vesicles A Strategy Towards Mitochondrial Gene Therapy
Current Pharmaceutical Biotechnology Peptides Derived from Platelet Non-integrin Collagen-receptors or Types I and III Collagen Inhibit Collagen-Platelet Interaction
Cardiovascular & Hematological Disorders-Drug Targets Oxidative Stress and Opioids' Toxicity: An Update
Mini-Reviews in Organic Chemistry Gene Therapy: How to Target the Kidney. Promises and Pitfalls
Current Gene Therapy Mitochondrially-Targeted Therapeutic Strategies for Alzheimer’s Disease
Current Alzheimer Research The Pivotal Role of Nitric Oxide: Effects on the Nervous and Immune Systems
Current Pharmaceutical Design The Role of Platelets in Athero-Thrombotic Events
Current Pharmaceutical Design Sodium Ion Transporters as New Therapeutic Targets in Heart Failure
Cardiovascular & Hematological Agents in Medicinal Chemistry Single-Photon Emission Computed Tomography Tracers for Predicting and Monitoring Cancer Therapy
Current Pharmaceutical Biotechnology Amyloid β -Protein Assembly as a Therapeutic Target of Alzheimers Disease
Current Pharmaceutical Design Recent Progresses in Application of Fullerenes in Cosmetics
Recent Patents on Biotechnology Lipoxygenase: An Emerging Target for Stroke Therapy
CNS & Neurological Disorders - Drug Targets The Effects of Erythropoietin on the Respiratory Function: Measurements of Respiratory Mechanics in the Rat
Current Respiratory Medicine Reviews Proresolution Mediators and Receptors: Novel Drug Targets for Enhancing Pharmacological Armamentarium against Periodontal Inflammation
Infectious Disorders - Drug Targets Pharmacologic Treatment of Pulmonary Arterial Hypertension
Current Pharmaceutical Design Activated Protein C: A Promising Drug with Multiple Effects?
Mini-Reviews in Medicinal Chemistry